Zimbabwe has rejected a major US healthcare agreement worth $367m (£272m) spanning five years due to Washington's insistence on sensitive information.
This rejection was revealed after a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa felt the agreement was "skewed".
A government representative has since explained that the US was seeking health data for scientific study and commercial purposes while was not willing to guarantee the benefits from future vaccines.
"We are forced to start the difficult and regrettable process of scaling back our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further negotiations to reach a agreement agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Context
This development follows a similar case in neighbouring Kenya, where a high court suspended a similar deal with the US following concerns were raised about the security of Kenyans' health data.
After returning to office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance openness and accountability.
As per reports, 16 nations in Africa have so far signed similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no corresponding assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," he stated.
"Effectively, our country would supply the raw materials for scientific discovery with no assurance that the end products would be available to our population if a new disease outbreak emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining frameworks previously set up through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with future pandemics.
"This framework is intended to guarantee that when a nation provides its information, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how future collaboration might be arranged in a way that respects the sovereignty and dignity of both nations."
Medical Community Response
A leading public health body said it understood the official position, but recommended that negotiations should continue since a large portion of the country's HIV programmes were funded by foreign aid.
"If technical issues arise, such as those involving data governance or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," the group commented.
The situation highlights the complex debate between accepting vital foreign assistance and safeguarding national sovereignty in an increasingly interconnected world.